Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03941379 · ClinicalTrials.gov registry record
A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma
A clinical trial of Choroidal Melanoma and Indeterminate Lesions of Eye, sponsored by Aura Biosciences.
- Recruiting
- Registry status
- 500
- Enrollment target
- 16
- Study locations
NCT03941379: Recruiting study of Choroidal Melanoma and Indeterminate Lesions of Eye, sponsored by Aura Biosciences.
NCT03941379 is a study of Choroidal Melanoma and Indeterminate Lesions of Eye that is actively recruiting participants, run by Aura Biosciences. The registered enrollment target is 500 participants, above the 50-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (900% higher). The trial reports 16 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03941379, a study of Choroidal Melanoma and Indeterminate Lesions of Eye, is actively recruiting participants, sponsored by Aura Biosciences.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 16
- Study locations
Study Summary
The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.
Conditions Studied
Study Locations (16)
California
- UCLA Jules Stein Eye Institute - Los Angeles
- Byers Eye Institute at Stanford University - Palo Alto
- Retina Consultants of Sacramento - Sacramento
Michigan
- W. K. Kellogg Eye Center, University of Michigan - Ann Arbor
- Associated Retinal Consultants, PC - Royal Oak
Texas
- Texas Retina Associates - Dallas
- Retina Consultants of Houston - Houston
Arizona
- Retina Associates SW, P.C. - Tucson
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Minnesota
- Retina Center - Minneapolis
New York
- Columbia University Medical Center - New York
Oregon
- Oregon Health & Science University Casey Eye Institute - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2019-03-27 |
| Est. Completion | 2029-12 |
What NCT03941379 shows while recruiting
NCT03941379 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 50-participant average among 3 other Choroidal Melanoma trials with a reported enrollment target (900% higher).
The record links to 2 conditions, with Choroidal Melanoma appearing as the primary indexed condition, and to 0 interventions.
NCT03941379 lists 16 locations in 12 states (California, Michigan, Texas).
Frequently Asked Questions
What is clinical trial NCT03941379 about?
NCT03941379 is a clinical study titled "A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma". The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and ef...
What is the current status of trial NCT03941379?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2019-03-27. Estimated completion is 2029-12.
What conditions does trial NCT03941379 study?
This clinical trial studies the following conditions: Choroidal Melanoma, Indeterminate Lesions of Eye.
Who is sponsoring clinical trial NCT03941379?
This trial is sponsored by Aura Biosciences, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03941379 being conducted?
This trial has 16 study locations across Arizona, California, Massachusetts, Michigan, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroidal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2)
COMPLETED · Phase 2
-
Ranibizumab in Combination With Proton Beam Irradiation for Choroidal Melanoma
COMPLETED · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI